Cure 360: MECP2 Reactivation | Interview with Toni Bedalov, MD, PhD | Rett Syndrome Research Trust

Toni Bedalov, MD, PhD, is one of several scientists collaborating on an MECP2 reactivation approach to cure Rett syndrome, which aims to awaken the healthy and silenced MECP2 gene in every girl with Rett. In collaboration with the labs of Kyle Fink, PhD, and Shawn Liu, PhD, Dr. Bedalov is using epigenome editing to achieve reactivation. Learn more in this short interview about current technologies and promising discoveries related to MECP2 reactivation that make Dr. Bedalov so hopeful about this genetic-based strategy for a Rett syndrome cure.
---------------------------------
The Rett Syndrome Research Trust is singularly focused on a cure for Rett syndrome and related MECP2 disorders. Achieving success takes a deep understanding of the relevant science, an environment built for scientific collaboration, and experience with drug and business development. Today we are building on incredible scientific and industry momentum by implementing six genetic-based strategies that tackle Rett from every angle. Every single company pursuing a cure for Rett is able to do so because they leveraged discoveries and resources that were generated with RSRT funding. RSRT is the home of the Rett cure community, and we are confident that together we will cure Rett syndrome.